Clinical trials: in Hungary
Non-Small Cell Lung Cancer
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally…
- Trial name
- TROPION-Lung10 (NCT06357533)
- Testing
- Datopotamab Deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 290 sites in United States, Australia and 19 more
- Volunteers
- 675 people
- Sponsor
- AstraZeneca
Plaque Psoriasis
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: Does ESK-001 reduce the severity of people's psoriasis? How safe is ESK-001 in…
- Trial name
- ONWARD2 (NCT06588738)
- Testing
- Envudeucitinib, Apremilast
- Where
- 124 sites in United States, Austria and 10 more
- Volunteers
- 862 people
- Sponsor
- Alumis Inc
Bronchiectasis
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations).
- Trial name
- NCT06872892
- Testing
- BI 1291583
- Where
- 478 sites in United States, Argentina and 44 more
- Volunteers
- 1,755 people
- Sponsor
- Boehringer Ingelheim
Psoriatic Arthritis (PsA)
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
- Trial name
- KEEPsAKE2 (NCT03671148)
- Testing
- Risankizumab
- Where
- 138 sites in United States, Argentina and 23 more
- Volunteers
- 444 people
- Sponsor
- AbbVie
Heart Failure
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more.
- Trial name
- NCT06424288
- Testing
- vicadrostat, empagliflozin
- Where
- 671 sites in United States, Argentina and 28 more
- Volunteers
- 6,712 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, Hypertension
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
- Trial name
- NCT07064473
- Testing
- Vicadrostat, Empagliflozin
- Where
- 1,142 sites in United States, Argentina and 49 more
- Volunteers
- 11,800 people
- Sponsor
- Boehringer Ingelheim
Migraine
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine.
- Trial name
- OASIS(CM) (NCT03832998)
- Testing
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
- Where
- 101 sites in United States, Belgium and 11 more
- Volunteers
- 284 people
- Sponsor
- Amgen
Systemic Lupus Erythematosus
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE.
- Trial name
- NCT07409181
- Testing
- BI 3000202
- Where
- 139 sites in United States, Argentina and 19 more
- Volunteers
- 405 people
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche sponsored Parent study who continue to receive ocrelizumab or are in safety…
- Trial name
- OLERO (NCT05269004)
- Testing
- Ocrelizumab
- Where
- 232 sites in United States, Argentina and 35 more
- Volunteers
- 1,300 people
- Sponsor
- Hoffmann-La Roche
Plaque Psoriasis
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
- Trial name
- NCT07116967
- Testing
- Deucravacitinib, Ustekinumab
- Where
- 411 sites in United States, Argentina and 23 more
- Volunteers
- 3,040 people
- Sponsor
- Bristol-Myers Squibb
Diabetic Retinopathy
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study.
- Trial name
- NCT06321302
- Testing
- BI 764524, Aflibercept (Eylea®) - US only
- Where
- 90 sites in United States, Germany and 7 more
- Volunteers
- 175 people
- Sponsor
- Boehringer Ingelheim
Acute Kidney Injury, Fluid Overload
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
There is a growing focus on short- and long-term kidney health in neonates, including those with acute kidney injury (AKI). AKI occurs commonly in the Neonatal Intensive Care Unit (NICU) and is associated with adverse outcomes.
- Conditions
- Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors
- Trial name
- AWAKEN 2 (NCT06823115)
- Where
- 125 sites in United States, Argentina and 31 more
- Volunteers
- 8,000 people
- Sponsor
- Indiana University
Heart Failure
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%.
- Trial name
- NCT06935370
- Testing
- vicadrostat, empagliflozin
- Where
- 594 sites in United States, Argentina and 27 more
- Volunteers
- 4,200 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Squamous Cell Carcinoma
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
This study is open to adults with head and neck cancer. The purpose of this study is to find out whether combining different study medicines makes tumors shrink in people with head and neck cancer.
- Trial name
- NCT06806852
- Testing
- BI 770371, Pembrolizumab, Cetuximab
- Where
- 51 sites in United States, Australia and 20 more
- Volunteers
- 91 people
- Sponsor
- Boehringer Ingelheim
Hepatic Encephalopathy
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE)…
- Trial name
- RED-C-3132 (NCT05297448)
- Testing
- Rifaximin SSD
- Where
- 188 sites in United States, Australia and 15 more
- Volunteers
- 517 people
- Sponsor
- Bausch Health Americas, Inc.
Lupus Nephritis
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
- Trial name
- IRIS (NCT05138133)
- Testing
- Anifrolumab
- Where
- 164 sites in United States, Argentina and 22 more
- Volunteers
- 363 people
- Sponsor
- AstraZeneca
Ovarian Cancer
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2…
- Trial name
- DO-01 (NCT06819007)
- Testing
- Trastuzumab Deruxtecan, Bevacizumab
- Where
- 232 sites in United States, Australia and 24 more
- Volunteers
- 582 people
- Sponsor
- Daiichi Sankyo
Lung Transplant Rejection
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of…
- Trial name
- ROCKaspire (NCT06082037)
- Testing
- Belumosudil, Azithromycin
- Where
- 85 sites in United States, Australia and 18 more
- Volunteers
- 180 people
- Sponsor
- Sanofi
Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves…
- Trial name
- NCT07472517
- Testing
- obrixtamig, atezolizumab, carboplatin
- Where
- 243 sites in United States, Argentina and 40 more
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
This study is open to adults who are at least 18 years old living with obesity and have: a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and moderate or advanced…
- Trial name
- NCT06632444
- Testing
- Survodutide
- Where
- 532 sites in United States, Argentina and 35 more
- Volunteers
- 1,800 people
- Sponsor
- Boehringer Ingelheim